Last reviewed · How we verify
Mycosis fungoides
Approved treatments
- Solu-Cortef · Pfizer
- Valchlor · Recordati
Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death. - Cortifoam · Pfizer
- Cortone
- Celestone Soluspan
- Decadron · Generic (originally Merck)
- Poteligeo · Kyowa Kirin
Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells. - Cyclophosphamid · Zhejiang University
- Vinblastin · The Lymphoma Academic Research Organisation
- Poteligeo · Kyowa Kirin Pharmaceutical Development Ltd
- prednison · Wen Zhang
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Cortef · Generic (originally Merck/Upjohn)
- Rodinolone
- Deltasone · Generic (originally Schering)
- Cytoxan (Lyophilized) · Baxter
Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites. - Depo-Medrol · Pfizer
Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response. - Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Cytoxan (Lyophilized) · Baxter
Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Mogamulizumab-Kpkc · H. Lee Moffitt Cancer Center and Research Institute
12.1 Mechanism of Action Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells. - Methotrexat · Biocad
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
- Methylprednisolon · Leiden University Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mycosis fungoides patent landscape — cliff calendar, originator estates, attackable patents
- Mycosis fungoides treatment landscape brief
- Mycosis fungoides treatment updates RSS
Frequently asked questions about Mycosis fungoides
What drugs treat Mycosis fungoides?
Tracked treatments include Solu-Cortef, Valchlor, Cortifoam, Cortone, Celestone Soluspan, Decadron, Poteligeo, Cyclophosphamid.
What is the treatment for Mycosis fungoides?
Standard treatment for Mycosis fungoides includes Solu-Cortef, Valchlor, Cortifoam, Cortone, Celestone Soluspan. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mycosis fungoides patent cliff · Mycosis fungoides CI report
- Treatment: Solu-Cortef · Pfizer
- Treatment: Valchlor · Recordati
- Treatment: Cortifoam · Pfizer
- Treatment: Cortone
- Treatment: Celestone Soluspan
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing